welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Welcome to your weekly digest of approaching regulatory and clinical readouts. Novavax is up 4% today thanks to topline results from a phase II trial showing that its Nanoflu influenza vaccine caused “vigorous immune responses” to four strains of flu, and that these responses were enhanced when the group’s Matrix-M adjuvant was added to the vaccine.
But an even more meaningful event is approaching. Novavax’s lead asset, a vaccine against respiratory syncytial virus, is in phase III, and after its disastrous failure two years ago in a study that was intended to be pivotal this is its last chance.
Resvax, also known as RSV F Vaccine since it targets the fusion protein of the virus, crashed out of the Resolve trial, testing it in prevention of moderate to severe RSV-associated lower respiratory tract disease, in mid-2016.
expertly curated content related to this topic
-
Colorectal Cancer GuidelinesThe American Society of Colon and Rectal...
-
Phenotype and Management of Patients with Familial Adenomatous Polyposis in Hong Kong: Perspective of the Hereditary...OBJECTIVES : To report on the phenotypic...
-
Lynch Syndrome and MYH-Associated Polyposis: Review and Testing StrategyIndividuals with Lynch syndrome have an ...
-
Colonoscopy Performed in Retroflexed Maneuverhttps://www.youtube.com/watch?v=doSRgguF...
-
Hereditary Colorectal Cancerhttps://www.fascrs.org/patients/disease-...
-
A de novo Desmoid Tumor of the Surgical Site Following Foramen Magnum Meningioma Resection in a Patient with Gardner...BACKGROUND : Gardner's Syndrome is a fam...
-
So, When Should You Actually Start Getting Colonoscopies?Colonoscopies help doctors find ulcers, ...